Latest News
All Times Eastern
- ‘It’s caused a lot of tension in our marriage’: My wife’s family comes visit, hides food and never cleans up. How do we get rid of them?
- Barron's China’s AI Clout Might Be Overstated. What to Know.
- Barron's This Company Makes Costco and Amazon’s Store Brands. Its Stock Is a Buy.
- Barron's This Carbon-Capture Stock Has Big Plans. Why It’s a Buy.
- Barron's Forget Apple and Nvidia. Why June Belongs to Small-Caps.
- Barron's Market Gains as Wall of Worry Crumbles. What Happens Next.
- Judge in FTX bankruptcy rejects media challenge, says customer names can remain secret
- Barron's Commercial Traders Are Net Long Copper. That’s a Good Sign for the Red Metal.
- Mark Zuckerberg says Meta may be ‘primary beneficiary’ of Apple Vision Pro headset
- Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
to be replaced
Novocure Ltd.
NVCRUS
$
0.24
0.56%
After Hours
$
43.00
After Hours Volume:
9.57K
| Close | Chg | Chg % |
|---|---|---|
| $42.76 | -2.74 | -6.02% |
Volume: 4.01M
65 Day Avg: 1.08M
42.00
Day Range
45.61
42.00
52 Week Range
120.03
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
NVCR Overview
Key Data
- Open $45.54
- Day Range 42.00 - 45.61
- 52 Week Range 42.00 - 120.03
- Market Cap $4.83B
- Shares Outstanding 106.21M
- Public Float 104.14M
- Beta 1.17
- Rev. per Employee $395.81K
- P/E Ratio N/A
- EPS -$1.34
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 8.08M 05/31/23
- % of Float Shorted 7.76%
- Average Volume 1.08M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 7
Full Ratings
Recent News
Novocure upgraded to outperform from perform at Oppenheimer
Novocure upgraded to buy from hold at Truist
Novocure downgraded to underperform from neutral at Wedbush
Novocure stock price target raised to $172 from $103 at J.P. Morgan
Novocure stock price target raised to $242 from $175 at Mizuho
Novocure stock price target raised to $242 from $175 at Mizuho
Novocure's stock rockets into record territory after upbeat DMC review of lung cancer treatment trial
Shares of Novocure Ltd. skyrocketed 80.7% toward a record high in premarket trading Tuesday, after the tumor treatment company said an independent data monitoring committee (DMC) said the interim analysis of a Phase 3 tri...
Novocure stock price target raised to $175 from $150 at Mizuho
Novocure stock price target raised to $150 from $84 at Mizuho
Novocure downgraded to hold from buy at Truist
Novocure downgraded to perform from outperform at Oppenheimer
Novocure stock price target cut to $82 from $91 at Mizuho
Novocure stock price target cut to $82 from $91 at Mizuho
Stocks That Hit 52-Week Lows On Wednesday
on Benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
on Benzinga.com
Looking At NovoCure's Recent Unusual Options Activity
on Benzinga.com
These 2 Nasdaq Stocks Are Plunging. Here's Why
on Motley Fool
Dow Falls Over 100 Points; Hoth Therapeutics Shares Spike Higher
on Benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
on Benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
on Benzinga.com
The Latest Analyst Ratings for NovoCure
on Benzinga.com
Nasdaq Edges Higher; Joann Shares Plummet
on Benzinga.com
Why NovoCure Stock Is Crashing Today
on Motley Fool
Dow Drops 50 Points; J.M. Smucker Earnings Top Views
on Benzinga.com
H.C. Wainwright Remains a Buy on NovoCure (NVCR)
on TipRanks.com
3 No-Brainer Stocks to Buy for Under $100 Right Now
on Motley Fool
Piper Sandler Sticks to Their Hold Rating for NovoCure (NVCR)
on TipRanks.com
NovoCure's Return On Capital Employed Overview
on Benzinga.com
Novocure Ltd.
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.